Treatment result for the terminal cancer with Large dose of Tiandicin

39 patients were treated by supporting theraphy alone and supporting theraphy plus high dose .Tiandicin from October,1996 to March 1997. Results :The median survial period and the rate for impovement of appetite were 15.4 weeks and 45%(9/20) in combination theraphy group and 7.79 weeks and 0%in supporting theraphy alone group (P<0.01). Conclusion :Using high dose Tiandicin and supporting theraphy will not only lengthen the lifetime of the terminal cancerous patients but also improve the quality of life.